Navigation Links
Genaera Corporation Announces Results of Special Meeting of Stockholders
Date:6/5/2009

PLYMOUTH MEETING, Pa., June 5 /PRNewswire-FirstCall/ -- Genaera Corporation ("the Company") (Nasdaq: GENR) today announced that proxies representing a majority of the shares voted at the Special Meeting of Stockholders on June 4, 2009 were cast in favor of the resolution to approve a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution).

About Genaera

Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as from other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

www.genaera.com


'/>"/>
SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors
2. Genaera Corporation Implements Cash Conservation Plan
3. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
4. Genaera Corporation Announces 2008 Financial Results
5. Genaera to Present at BIO CEO & Investor Conference
6. Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
7. Genaera to Present at Therapeutic Area Partnerships 2008
8. Genaera Receives Non-Compliance Notice From NASDAQ
9. Genaera Corporations 2008 Annual Stockholder Meeting Results
10. Xmark Comments on Genaera Cost-Saving Plan
11. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding its Graduate Business ... will be expanding due to high demand: Master of Business Administration (MBA), Master of ... summer. , School of Business Graduate Program Chair Dr. Ray Manganelli said: ...
(Date:4/29/2016)... Newport Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... affect us. An effective way to confront and deal with these stressors is to ... taste bad to be good for you. Risa Groux, a certified Holistic Nutritionist and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Conditions were ideal ... Cove Island Park on Sunday, with sunny skies, a light breeze and temperatures in ... $33,000. , The 5k Run and Walk and 1-mile walk were held ...
(Date:4/29/2016)... ... , ... Mobility Designed is redefining mobility with their patent pending crutch ... evenly distributes body weight from the elbow to the forearm. In consumer tests, ... with other crutches. , Co-founders Max and Liliana Younger were inspired to design the ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
(Date:4/27/2016)... TURIN, Italy , April 27, 2016 ... MR-guided linear accelerator (MR-linac) platform will be the focal ... annual meeting of the European Society for Radiotherapy & ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and ... a physician to clearly see the patient,s anatomy in ...
Breaking Medicine Technology: